GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Net Change in Cash

NGNE (Neurogene) Net Change in Cash : $-11.79 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neurogene Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Neurogene's Net Change in Cash for the three months ended in Dec. 2024 was $69.95 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was $-11.79 Mil.

Neurogene Net Change in Cash Historical Data

The historical data trend for Neurogene's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Net Change in Cash Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Change in Cash
-13.71 11.48 66.70 -11.79

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 103.16 1.76 -39.11 -44.40 69.95

Neurogene Net Change in Cash Calculation

Neurogene's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-70.603+-125.261+184.071+0
=-11.79

Neurogene's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-17.496+-102.616+190.065+0
=69.95

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Neurogene's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurogene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Net Change in Cash
Comparable Companies
DSGN SLRN PRME GOSS PLX KOD HUMA OABI OCGN THRD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
UU8:Germany
Address
535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Website
https://www.neurogene.com
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.